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Pseudomonas aeruginosa secretes several proteases associated with pathogenesis, but the most 
abundant and active is elastase (M4 metalloendopeptidase). Elastase (lasB), is first synthesized 
as a preproenzyme, with a signal peptide, an 18-kDa N-terminal propeptide, and a 33-kDa 
mature domain.  The propeptide functions as an intramolecular chaperone that is required for the 
folding and secretion of elastase, but ultimately is proteolytically removed and degraded.  
Previous research has identified the conserved residues in the propeptide of elastase as compared 
to other M4 protease precursors and showed some among them to be important for the 
production of active elastase.  In this project, the ability of the propeptide alone to fold into a 
defined secondary structure was explored and a molecular model was created.  Furthermore, the 
effects of substitutions on conserved residues in the propeptide of plasmid-encoded lasB pro 
alleles were assessed by expressing them in a lasB propeptide mutant.  The kinetics of elastase 
activity in culture supernatants was quantitated using a fluorescent substrate, Abz-AGLA-p-





vitro refolding studies were also performed to determine the effects of specific substitutions on 
foldase activity of the propeptide. When wild-type propeptide and mature elastase were 
denatured as separate proteins in guanidine-HCl buffer and renatured together, restoration of 
activity of the refolded elastase was measured, which was propeptide-dependent. Several mutant 
propeptides have now been shown to have defects using this in vitro foldase assay.  Additional 
mutants were near wild-type activity level suggesting their role in recognition by the secretion 
apparatus.  Residue locations were determined on a molecular model of the complex and 
confirmed the role of the secretion mutants as residues on the exterior.  Residues that had 
diminished ability to refold in the in vitro assay were found to be in the interior parts of the 
complex, confirming their ability to be critical residues at the interface of the proteins or 
important in the stability of the propeptide’s intrinsic structure.  The goal was to perform a series 
of comprehensive analyses of the propeptide and its conserved residues in order to determine its 






Pseudomonas aeruginosa infections 
 In January of 2009, Pseudomonas aeruginosa made international headlines in the medical 
community (Bradley Brooks, 2009).  A beautiful young woman arrived in a Brazilian hospital in 
septic shock.  Within two weeks, her feet and hands were amputated and she passed away days 
later.  Mariana Bridi da Costa, a 20-year old Brazilian model and Miss World Finalist, had gone 
to the hospital right before the New Year complaining of kidney pain.  She was quickly 
diagnosed with kidney stones and sent home.  Within four days, her blood pressure had 
plummeted and her body went into septic shock.  The Pseudomonas aeruginosa organism had 
entered her bloodstream and was quickly spreading through her body.  In an effort to control the 
spread, her necrotic limbs were amputated but she succumbed to the infection in less than a 
month after the initial complaint. 
 Pseudomonas aeruginosa is a microorganism that exploits the human body to initiate a 
fatal infection.  P. aeruginosa is a Gram-negative, aerobic bacillus of the Gammaproteobacteria 
class(Iglewski, 1996).  This particular bacterium is the quintessential opportunistic pathogen of 
humans.  It can infect nearly every tissue and system in the human body but rarely infects a 
healthy host.  Furthermore, it is resistant to many antibiotics, and can mutate rapidly to become 
resistant to new drugs.  This is a grave problem in patients that are hospitalized, particularly 
those with cancer, cystic fibrosis, and burns, where the noscomial infection fatality rate is 
50%(Lyczak, Cannon, & Pier, 2000).  In addition to these immune-compromised conditions, P. 
aeruginosa can cause a number of other diseases such as urinary tract infections, endocarditis, 





   Hospital-acquired infections are costly to the health-care system and a target of 
numerous strategies.  This bacterium is particularly troublesome for hospitals because it is 
physically adaptive to diverse conditions.  While its optimum growth temperature is 37°C, it is 
able to grow in lower and higher temperatures (Silo-Suh, Elmore, Ohman, & Suh, 2009).  It is 
resistant to high salt concentrations and has very simple nutritional needs, requiring only acetate 
as a source of carbon and ammonium sulfate as a source of nitrogen.  This organism can grow in 
soil and moist environments(Stratton, 1983) including hospital reservoirs: bottles of 
disinfectants, respiratory equipment, food, sinks, taps, toilets, showers and mops.  It is constantly 
reintroduced into the hospital environment through fruits, plants, vegetables, as well by visitors 
and patients transferring from other facilities (Pitten, Panzig, Schroder, Tietze, & Kramer, 2001). 
Spread occurs from patient to patient through the hands of hospital personnel, by direct patient 
contact with contaminated reservoirs and by the ingestion of contaminated foods and water. The 
bacteria can form persistent biofilms. In its planktonic form it is free swimming, constantly 
looking for its next safe harbor (Jensen, Givskov, Bjarnsholt, & Moser, 2010). The spread of P. 
aeruginosa can best be controlled by observing proper isolation procedures, aseptic technique, 
and careful cleaning and monitoring of respirators, catheters, and other instruments (Pitten et al., 
2001). Topical therapy of burn wounds with antibacterial agents such as silver sulfadiazine, 
coupled with surgical debridement, dramatically reduces the incidence of P. aeruginosa sepsis in 
burn patients(Shanmugasundaram, Uma, Ramyaa Lakshmi, & Babu, 2009). 
Besides its ability to thrive in a number of hospital settings, Pseudomonas aeruginosa is 
notorious for its antibiotic resistance.  The Gram-negative outer membrane affords the first level 
of antibiotic resistance to the organism. Additionally, its ability to form biofilms allows the 





the extracellular matrix in order to affect the organisms (Davies & Bilton, 2009). Pseudomonas 
is able to maintain antibiotic resistance plasmids and transfer resistance genes by horizontal gene 
transfer via transduction and conjugation (Qiu, Kulasekara, & Lory, 2009).  A limited number of 
antibiotics are successful against Pseudomonas aeruginosa (Wiener-Kronish & Pittet, 2011).  
These include fluoroquinolones, gentamicin, and imipenem but even these are not effective on 
all the strains. Several types of vaccines are being tested, but none are currently available for 
general use. 
 Diagnosis of P. aeruginosa infection depends upon isolation and laboratory identification 
of the bacterium. It grows well on most laboratory media and commonly is isolated on blood 
agar or eosin-methylthionine blue agar (Tielen et al., 2011). It is identified on the basis of its 
Gram stain morphology, inability to ferment lactose, a positive oxidase reaction, its fruity odor, 
and its ability to grow at 42°C (Tomlin, Coll, & Ceri, 2001).  The colonies also fluoresce under 
ultraviolet light.  This can be used to diagnose P. aeruginosa in wounds. 
 In addition to the ability of the organism to live in even the most harshest of 
environmental conditions, P. aeruginosa employs a number of virulence factors.  A number of 
virulence factors (Figure 1) aid in adhesion. The bacterium has a single polar flagellum utilized 
for motility and dissemination (Conrad et al., 2011).  The manner in which P. aeruginosa uses 
these virulence factors is resourceful.  To first colonize, the organism needs the host to have a 
significant break in the first line of defense.  This can include surgical trauma, tears and 
abrasions, or burns in the skin or mucosal areas (Pruitt, McManus, Kim, & Goodwin, 1998).  
Additionally, this can occur with the disruption of the normal human flora through the use of 
broad-spectrum antibiotics or a lapse in the immunologic defense mechanisms. Such a lapse can 
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Figure 1. Virulence Factors of Pseudomonas aeruginosa. 
(A) The virulence factors associated with the bacterium, Pseudomonas aeruginosa.  They are 
classified by how the organism uses them to exploit the host to first colonize (adhesions), 
evade the host immune system (invasions), and move deeper into the host (motility and 
toxins). These individual virulence factors can play multiple roles in pathogenesis. Some 
of these are listed in the right-hand column. 
(B) An illustration of the location of those some of the key virulence factors of Pseudomonas 



















cystic fibrosis patient (Fujitani, Sun, Yu, & Weingarten, 2011).  The first step in colonization is 
the “opportunisitic adherence” of the bacteria to compromised epithelium, typically using the 
bacteria’s pili (Hertle, Mrsny, & Fitzgerald, 2001).  The pili of Pseudomonas aeruginosa can 
adhere to the epithelial cells. The adhesins bind to specific galactose or mannose or sialic acid 
receptors on epithelial cells (Heiniger, Winther-Larsen, Pickles, Koomey, & Wolfgang, 2010).  
Colonization can also be aided by proteases which degrade fibronectin to further expose the pili 
receptor on the epithelial cell surface (Azghani, Kondepudi, & Johnson, 1992).  After initial 
adhesion, pathogenesis can cause a chronic infection or an acute infection.    
During a chronic lung infection seen in P. aeruginosa colonized patients with cystic fibrosis, 
the organism produces only low levels of non-cell associated virulence factors, such as toxins 
and proteases (Tingpej et al., 2007).  This allows the bacteria to have sustainability in the host, 
using precious energy only to gather nutrients and build protective microcolonies (Mabrouk, 
Deffuant, Tolker-Nielsen, & Lobry, 2010).  These microcolonies are protected further by the 
cell-associated virulence factors like alginate (Hay, Gatland, Campisano, Jordens, & Rehm, 
2009), an exopolysaccharide that can aid in adhesion. Alginate allows for reduced clearance of 
the bacteria from the lung (Boucher, Yu, Mudd, & Deretic, 1997).  It works to anchor the cells to 
their environment and, in medical situations, it protects the bacteria from the host defenses such 
as lymphocytes, phagocytes, the ciliary action of the respiratory tract, antibodies and 
complement (Song et al., 2003). The alginate allows for the P. aeruginosa infection to persist in 
the host for years.  
However in acute infections, the ability of Pseudomonas aeruginosa to invade host tissues 
depends upon production of extracellular enzymes and toxins that break down physical barriers 





defenses (Adekoya & Sylte, 2009).  Oftentimes, these acute infections can be introduced in the 
hospital setting.  The introduction of bacteria into burn wounds is quite easy if non-sterile 
techniques are used.  This can provide efficient bacterial colonization of the exposed, 
compromised epithelial tissues.  The bacteria now use cell-to-cell signaling to amplify the 
extracellular virulence factors, such as toxins and proteases, to aid in dissemination (Parsek & 
Greenberg, 2000).  These proteases can break down tissue integrity and inactivate host response 
molecules to allow the organism to migrate into the other tissues and the bloodstream. 
 This is however, a small view of the destructive capabilities of the organism.  
Pseudomonas aeruginosa can cause a number of other debilitating diseases.  The organism 
infects heart valves of IV drug users as well as prosthetic heart valves by establishing itself on 
the endocardium by direct invasion from the blood stream(Reyes, Ali, Mendes, & Biedenbach, 
2009).  Respiratory infections caused by Pseudomonas aeruginosa occur almost exclusively in 
individuals with a compromised lower respiratory tract or a compromised systemic defense 
mechanism (Zemanick, Sagel, & Harris, 2011) . Primary pneumonia occurs in patients with 
chronic lung disease and congestive heart failure(Sun, Fujitani, Quintiliani, & Yu, 2011). 
Bacteremic pneumonia commonly occurs in neutropenic cancer patients undergoing 
chemotherapy (Fujita, Gu, Kishida, Okinaka, & Ohmagari, 2010).  Lower respiratory tract 
colonization of cystic fibrosis patients by mucoid strains of Pseudomonas aeruginosa is quite 
common and difficult, if not impossible, to eradicate (Zemanick et al., 2011). 
Pseudomonas aeruginosa can cause bacteremia primarily in immunocompromised 
patients and is acquired in hospitals and nursing homes (Fujimura, Nakano, Takane, Kikuchi, & 
Watanabe, 2011). Predisposing conditions include immunodeficiency resulting from AIDS, 





This organism also causes meningitis and brain abscesses (Mena & Gerba, 2009). It 
invades the CNS from a nearby structure such as the inner ear or paranasal sinus (Suzuki, 
Nishiyama, Sugiyama, Miyamoto, & Baba, 1996). It can be inoculated directly by means of head 
trauma, surgery or invasive diagnostic procedures, or spreads from a distant site of infection such 
as the urinary tract (Chang et al., 2010).    
Pseudomonas aeruginosa is the predominant bacterial pathogen in some cases of external 
otitis, including "swimmer's ear" (Reid & Porter, 1981). Pseudomonas aeruginosa can cause 
devastating infections in the human eye. It is one of the most common causes of bacterial 
keratitis (Stewart et al., 2011). Pseudomonas can colonize the ocular epithelium by means of a 
fimbrial attachment to sialic acid receptors (Wong, Sethu, Louafi, & Hossain, 2011). If the 
defenses of the environment are compromised in any way, the bacterium can proliferate rapidly 
through the production of enzymes such as elastase, alkaline protease and exotoxin A, and cause 
a rapidly destructive infection that can lead to loss of the entire eye (Twining, Kirschner, 
Mahnke, & Frank, 1993).   
Urinary tract infections (UTI) caused by Pseudomonas aeruginosa are usually hospital-
acquired and related to urinary tract catheterization, instrumentation or surgery. Pseudomonas 
aeruginosa is the third leading cause of hospital-acquired UTIs, accounting for about 12 percent 
of all infections of this type (Tielen et al., 2011). The bacterium appears to be among the most 
adherent of common urinary pathogens found in the bladder uroepithelium. In addition, 
Pseudomonas can invade the bloodstream through the urinary tract. Such infections account for 
nearly 40 percent of all Pseudomonas bacteremias infections (Shigemura et al., 2006), such as 





Pseudomonas aeruginosa can produce disease in any part of the gastrointestinal tract in 
immune-compromised individuals from the oropharynx to the rectum (Koh et al., 2010). It can 
also cause a variety of skin infections, both localized and diffuse. The common predisposing 
factors include a invasion of the integument which may result from burns, trauma or dermatitis; 
high moisture conditions such as those found in the ear of swimmers and the toe webs of 
athletes, hikers and combat troops, in the perineal region and under diapers of infants, and on the 
skin of whirlpool and hot tub users. Pseudomonas has also been implicated in folliculitis and 
unmanageable forms of acne vulgaris (Yu, Cheng, Wang, Dunne, & Bayliss, 2007). 
 
Significance of Pseudomonas proteases 
In a number of these disease types, bacterial proteases are often utilized in the organism’s 
pathogenesis.  Pseudomonas aeruginosa secretes several exoproteases, including elastase, lasA 
protease, and alkaline protease (Doring et al., 1987; Galloway, 1991). These are critical virulence 
factors, that work together to destroy tissue and damage host cell functions.   Specifically 
elastase, an M4 metallopeptidase, has been shown to cleave the different components of tissue 
structure, including fibrin, collagen and elastin (El-Bazza, Moroz, Glatman, Samoilenko, & 
Terekhov, 1988), while it can also impair host proteases and defense mechanisms (Dulon et al., 
2005).  This protease is the most abundant extracellular endopeptidase secreted by P. aeruginosa 
and allows the bacteria to circulate further through the host (Kessler, E., and D. Ohman., 2004) . 
 
Elastase: Function and Utility 
Elastase is named for its ability to digest elastin (Kessler, E., and D. Ohman., 2004).  





walls, lung, skin, and the bladder.  It is a connective fiber with elastic properties which allow the 
tissue to retain its shape after contraction and expansion.  Elastin also is primarily composed of 
four amino acids: glycine, valine, alanine, and proline.  Elastin fibers are linked together to make 
a large, insoluble, resilient cross-linked array and this mesh is notoriously difficult to degrade 
(Heck, Morihara, & Abrahamson, 1986).  Elastase is produced by over 80% of clinical isolates 
of P. aeruginosa (Wretlind, Heden, Sjoberg, & Wadstrom, 1973).  Second to the ability to 
destroy elastin, elastase has the ability to degrade fibrin and collagen barriers as well as 
inactivate additional host proteins, including alpha-1-proteinase inhibitor, bronchial mucus 
proteinase inhibitor, lysozyme, complement components, IgG and IgA, along with inactivating 
signal inflammation cascades (Doring, Obernesser, & Botzenhart, 1981; Heck et al., 1990; 
Holder & Neely, 1989; Jacquot, Tournier, & Puchelle, 1985; Johnson, Carter-Hamm, & Dralle, 
1982; Morihara, Tsuzuki, & Oda, 1979; Schultz & Miller, 1974).  In addition to pulmonary 
tissue, corneal tissue, urinary tract, and vascular destruction have been linked to elastase activity  
(Gray & Kreger, 1975; Heck, Morihara, McRae, & Miller, 1986; Shigemura et al., 2006).    
Elastase works syngergistically with LasA protease (E. Kessler, Safrin, Olson, & Ohman, 1993), 
a serine protease that nicks the elastin and renders it susceptible to other enzymes like elastase. 
Most of the destructive tissue pathogenesis of P. aeruginosa can be attributed to these secreted 
enzymes (Wretlind & Pavlovskis, 1983). 
  Regulation of the production of many of the Pseudomonas aeruginosa virulence factors, 
including these enzymes, is tightly controlled by a mechanism which monitors bacterial cell 
density and provides communication between the bacteria by cell-to-cell signaling.  Many gram-
negative and gram-positive bacteria have developed the ability to sense their environmental 





Greenberg, 2000).  This enables the bacteria to secrete the virulence factors only at optimal times 
for the pathogenesis.  The bacteria do this by producing a small molecule called an autoinducer 
(AI) which is free to diffuse through the cell membrane and away from the cell.  In low density 
populations, the AI diffuses away from the cell into the media and becomes diluted.  With 
increasing bacterial cell density, the concentration of this AI accumulates and reaches a threshold 
level. The small molecule is now able to bind a transcriptional activator protein, forming a 
complex which is able to bind DNA sequences upstream of target genes enhancing their 
transcription.  In Pseudomonas aeruginosa, there are two circuit systems that interact to ensure 
the precise and abundant production of elastase (Pearson, Pesci, & Iglewski, 1997).  The 
autoinducers responsible for elastase synthesis are 3-oxo-C12-HSL (N-[3-oxododecaolyl]-L-
homoserine lactone) and C4-HSL (N-butyrylhomoserine lactone)(Passador, Cook, Gambello, 
Rust, & Iglewski, 1993; Passador et al., 1996).  The AI synthase gene responsible for the first AI 
(3-oxo-C12-HSL), is lasI and the lasR gene codes for the transcriptional activator protein 
(Sappington, Dandekar, Oinuma, & Greenberg, 2011).  Additionally, the las system has been 
shown to activate the genes necessary for the transport of these enzymes from the cell (Rust, 
Pesci, & Iglewski, 1996).  
 The organism has a backup mechanism in the second circuit, the rhl system(Wilder, 
Diggle, & Schuster, 2011).  The second AI (C4-HSL) is encoded by the rhlI, the AI synthase 
gene, while the rhlR gene encodes the transcriptional activator protein (Netotea et al., 2009).  
This circuit has the ability to activate production of some of the same virulence factors but the 












Figure 2. The three domain polypeptide is illustrated.  The purple domain is the pre domain 
(called the signal sequence), the green domain is the propeptide domain, and on the carboxyl end 
is the mature domain indicated in red.  The residues highlighted on the mature domain (red) are 
those involved in the HEXXH motif (H140, E141, V142, S143, final H144), and additionally 






System (Wilder et al., 2011).  This intricate circuitry allows for the production of the virulence 
factors to be most beneficial for the organism.  
Additionally, the bacteria have evolved another way to control the mechanism of action 
of elastase.  Most prokaryotic proteases are synthesized as zymogens or inactive precursors 
(proenzymes) (Khan & James, 1998).  Both LasA protease and elastase secreted are proenzymes 
by P. aeruginosa (E. Kessler, Safrin, Gustin, & Ohman, 1998). These zymogens are normally 
activated only after the polypeptide has been localized to its predestined site of action, which can 
be either intracellularly or extracellulary.  Elastase is one of these zymogens and is encoded by 
lasB (Pseudomonas aeruginosa locus PA3742) (Stover et al., 2000; Winsor et al., 2009; Winsor 
et al., 2011).  This gene is located between 4170483 – 4168987 Mbp on the genome of strain 
PAO1 and encodes a 498 amino acid (53.6-kDa) protein, called pre-proLasB (Bever & Iglewski, 
1988; Fukushima et al., 1989).  This larger precursor (Figure 2) is composed of a 2.6 kDa (23 
residues) signal peptide that is followed by an 18 kDa (174 residues) propeptide and the 33 kDa 
mature domain (301 residues) (Bever & Iglewski, 1988).  However, only a 33-kDa protein is 
found in the culture supernatant (Wolz et al., 1991).  The aim of this project is to elucidate the 
role of the propeptide domain in folding and activating the mature domain. 
Initially all three domains are synthesized within the cytoplasm (Figure 3).  The signal 
peptide is removed upon secretion from the Sec system into the periplasm (Braun, Bitter, & 
Tommassen, 2000).  Once within the periplasm, the propeptide is autocatalytically cleaved and 
forms a non-covalent complex with the mature domain.  The mature domain also forms 
disulphide bonds within the periplasm (Braun et al., 2001).  This complex is recognized by the 
Type II secretion system (T2SS) and secreted into the extracellular
 
environment (Braun, 













Figure 3. The folding and secretion model of the zymogen known as Elastase.  Within the 
bacterial cytoplasm, all three domains of the polypeptide are seen.  The “pre” domain (signal 
sequence) is lost upon secretion into the periplasm via the Sec transport system.  The propeptide 
domain and the mature domain within the periplasm are then autocatalytically cleaved and 
folded into an inhibited complex.  Here the disulphide bonds also form in the mature domain.  
This inhibited complex is recognized by the Type II secretion system (Xcp transport system in 
Pseudomonas).  The inhibited complex is then transported extracellularly and the propeptide 
domain dissociates from the mature domain. It is degraded by the now active elastase and other 






which are generically named Gsp, or Xcp in the
 
case of the main T2SS in Pseudomonas 
aeruginosa (Filloux, Michel, & Bally, 1998). The Xcp system of P. aeruginosa is important for 
the secretion
 
of many different proteins, including elastase, lipase, phospholipases,
 
chitin-binding 
protein and exotoxin A (Koster, Bitter, & Tommassen, 2000). The system is encoded
 
by 12 xcp 
genes.  Production of the system is regulated by quorum sensing and it has been
 
estimated that 
50–100 Xcp complexes are present in the
 
cell at high cell densities (Russel, 1998). 
Initially the complex is seen outside the cell. However, after a short period of time, the 
abundant protein is found to be the 33-kDa mature domain (E. Kessler & Safrin, 1994).  Current 
research suggests that the propeptide appears to be critical for folding within the periplasm and 
secretion but not for the activity of the enzyme.  This function proposes a need for understanding 
the propeptide-mediated folding of the mature domain and catalysis of the individual complex 
components which are both required for final enzyme activation.   
 
Elastase: Structure 
Elastase is a member of the M4 family of Thermolysin-like Neutral zinc-metallo 
Proteases (TNP).  This protease has previously been termed Pseudolysin (EC 3.4.24.26), due to 
its 49% simillarity to Thermolysin, an M4 metalloprotease secreted by Bacillus 
thermoproteolyticus (Kessler, E., and D. Ohman., 2004). The crystal structure of the mature 
active enzyme has been solved to 1.5 angstrom resolution (Figure 4) (Thayer, Flaherty, & 
McKay, 1991).  Both proteases, elastase and thermolysin, contain a single zinc atom essential for 
activity, observed by metal chelation experiments inhibiting enzymatic activity (E. Kessler, 
Israel, Landshman, Chechick, & Blumberg, 1982).  The active site catalytic residue (Glu-141) 











Figure 4. (A) Shown is a ribbon diagram of the crystal structure of the mature domain of elastase 
(PDB 1EZM) by Dr. McKay in published in 1991.  The grey sphere in the middle right is the 
zinc ion, the left one is the calcium ion.  The two globular regions are shown by the presence of 
alpha helices and the beta strands. The amino terminus of the enzyme is seen at the bottom of the 
structure (bottom – left, second beta sheet in).  The carboxyl terminus is on the top (attached to 
the furthest red alpha helix).  
(B) Shown is a space filling model of the enzyme.  The residues in the substrate cleft are shown 






and Glu-166) (Kawamoto et al., 1993).  Elastase also requires calcium ions for stabilization 
(Olson & Ohman, 1992).  Additionally, substantial conformational differences were observed 
when the enzyme was either in the absence of ligand or in the presence of a covalent 
noncompetitive inhibitor as compared to tight-binding competitive inhibitors (McKay, Thayer, 
Flaherty, Pley, & Benvegnu, 1992).  The first group maintains an “open” substrate binding cleft 
while competitive inhibitors allow the cleft to close. 
Elastase favors certain residues for its substrate specificity.  Hydrophobic or aromatic 
amino acid residues are optimal for the residue that is just to the carboxyl terminus of the 
substrate cleavage site (P1' position).  The order of preference for residues at P1’ is Phe >Leu 
>Tyr >Val >Ile. Aromatic residues seem to be preferred to aliphatic residues (Kessler, E., and D. 
Ohman., 2004). Ala is favored at the P1 (the residue at the position amino terminal to the 
substrate cleavage) and P2' (carboxy to the P1’ residue) positions, and elongation of the substrate 
to the P2 and P2' positions results in a marked increase in the rate of hydrolysis (Kessler, E., and 
D. Ohman., 2004).  
The family of M4 metalloproteases is classified based on a number of characteristics.  
According to the MEROPS peptidase database, elastase is a member of the MA clan of 
peptidases.  The members of this clan have water bound by a single zinc ion which in turn is 
ligated to two His residues and Glu residue, and an additional His or Asp (Rawlings & Barrett, 
1993).  This clan contains a variety of metallopeptidases and all have the conserved HEXXH 
motif where the two His residues coordinate a zinc ion and the Glu has a catalytic function 
(Rawlings, Barrett, & Bateman, 2010).  Elastase is further classified within the M4 family of the 
MA clan.  Unique to the M4 family is the fact that the endopeptidases all bind a single zinc ion 





mature domain (Jongeneel, Bouvier, & Bairoch, 1989).  The zinc ion is tetrahedrally co-
ordinated and the fourth ligand is activated water, which forms the nucleophile in the catalysis 
reaction (Rawlings & Barrett, 1993). Most of the M4 family members are active at a neutral pH 
and degrade substrates with the preference of cleaving after hydrophobic residues and before 
Leu, Phe, Ile and Val (MEROPS).  Of the 22 members identified in this family, five have been 
crystallized, (thermolysin PDB: 1NPC, vibriolysin PDB: 3NQX, elastase PDB: 1EZM, 
aureolysin PDB: 1BQB, and protealysin PDB: 2VQX)(Banbula et al., 1998; Demidyuk et al., 
2010; Gao et al., 2010; Stark, Pauptit, Wilson, & Jansonius, 1992; Thayer et al., 1991).  The 
mature genetic domains have a two globular domain structure with the active site between the 
structural domains. They have N-terminal propeptides that are autocatalytically removed upon 
secretion of the enzymes from the cells.  However little is known about their propeptide 
domains.  The propeptide of elastase has two folds, identified by sequence homology in the Pfam 
protein fold database: PepSY and FTP (Braun et al., 2000).  The PepSY fold is likely to have a 
protease inhibitor function and the Fungalysin/Thermolysin Propeptide Motif fold (FTP) is likely 
to either inhibit the peptidase by preventing premature activation or acts as a chaperone for the 
mature domain. 
Currently, we understand that the propeptide is secreted with the enzyme and processing 
of the mature domain is autocatalytic (McIver, Kessler, Olson, & Ohman, 1995).  During this 
initial secretion time period, short-term Pseudomonas aeruginosa cultures showed that inactive 
elastase-propeptide complex is secreted from the cells (E. Kessler & Safrin, 1994).  Immunoblots 
(Figure 5) of these washed cell cultures, to limit proteolysis, confirm the presence of the 
propeptide in the supernatant for up to one hour, followed by degradation (E. Kessler & Safrin, 











Figure 5.  Washed cell culture assays were used to identify the time frame propeptide seen in the 
supernatant of cultures, modified from (E. Kessler & Safrin, 1994).  Cultures of P. aeruginosa 
were grown for 18 hrs and the cells were washed and resuspended in fresh media and protease 
inhibitors.  Aliquots of the culture were taken at designated time points (shown in minutes) and 
spun.  The supernatants were TCA precipitated and run on an SDS-PAGE and transferred.  
These immunoblots were probed with anti-Elastase antibodies (top panel) and anti-Propeptide 
antibodies (bottom panel).  Propeptide was found for up to an hour after induction, as seen by the 
band in the bottom panel. Afterwards, it is degraded.  This provides evidence that propeptide is 






extracellularly by elastase and other secreted active proteases (E. Kessler et al., 1998).  
Propeptide alone is not secreted from the cell (data not shown).  In vitro zymogram experiments 
have shown the propeptide acting as an effective inhibitor of the protease (E. Kessler & Safrin, 
1994).  When elastase is mixed with increasing volumes of periplasmic fractions (which contain 
the propeptide), and run on a zymogram using skim milk as a substrate, the elastase loses its 
activity. 
To further examine the interaction between the propeptide and elastase, studies were performed 
to overexpress the two components in trans in E. coli (McIver et al., 1995). While E. coli K12 
cannot secrete the active enzyme past the outer membrane due to the lack of Xcp transport 
machinery, the propeptide-enzyme complex is autoprocessed to an active enzyme form (33-kDa) 
while remaining in the periplasm, confirming the propeptide processing from the enzyme is 
autocatalytic.  A propeptide deletion allele (lasB6) was exchanged into the Pseudomonas 
chromosome and complemented with the propeptide expressed in trans (lasB7).  This system 
(Figure 6) showed elastase activity measured outside the cell. When the lasB6 allele, encoding a 
pre-mature segment without the propeptide, is expressed in E. coli, the enzyme product is 
inactive.  Expression of this propeptide deleted allele also resulted in the accumulation of the 
inactive enzyme within the cell.  The only way to restore activity of the enzyme was through co-
expression of the lasB7 allele encoding the pre-propeptide.  Therefore the propeptide is needed 
in cis or in trans for the secretion of the mature enzyme as well as for its activation.  
When specific amino acid residues on the mature domain, such as His-223 (substrate-
binding residue) are changed to Asp (lasB1) or Tyr (lasB2) in order to block proteolytic activity, 











Figure 6. The propeptide has been shown to interact with the mature domain in cis and in trans.  
Experiments examined the presence and absence of the propeptide domain (shown in green) on 
the ability to see active elastase.  When the propeptide was deleted (lasB6 allele), elastase 
activity was lost.  Complementing the propeptide back (lasB7 allele) on a plasmid, recovered the 






the membrane fraction(McIver, Olson, & Ohman, 1993).  These mature domain residues appear 
to be critical for autocatalysis of the propeptide from the mature domain.   
These experiments provided initial insight into the propeptide domain acting as an 
intramolecular chaperone (IMC) (McIver et al., 1995).  An IMC is typically a region of a protein 
that mediates a conformational change to that protein.  This includes the ability of that region 
(the propeptide) to be essential for proper folding and secretion of the propeptide-mature 
complex.  A number of the M4 propeptides have been thought to function as IMCs.  
These previous experiments were initially demonstrated that a TNP family member is an IMC-
containing protease.  Additionally if this propeptide is a chaperone to the enzyme, it would be 
expected that the two components would have direct interactions.  This was confirmed with co-
immunoprecipitation experiments (McIver et al., 1995).  Elastase/anti-elastase 
immunoprecipitates contain the propeptide, as determined by Western blots using propeptide-
specific antibodies (data not shown).  Furthermore, the non-covalent complex remains associated 
to permit the complex secretion across the outer membrane (McIver et al., 1995). 
The next step involved determining the residues within the propeptide that are required 
for chaperone activity (McIver, Kessler, & Ohman, 2004).  Homology alignments were 
performed, comparing the propeptide domain with propeptides of other TNPs sequenced at the 
time. Two regions of interest were found.  The first motif, ProM, is near the middle of the 
propeptide and contains hydrophilic residues. The second motif, ProC, is located at the C-
terminus and contains more hydrophobic residues.  This conservation suggests an evolutionary 
relationship of the TNP propeptides to retain essential folding functions.  To test whether these 
conserved motifs were important, single residue substitutions at eight conserved amino acids 





ProM motif, substitution at R74 resulted in an accumulation of propeptide-mature complex 
within the cell, suggesting a secretion defect.  Substitution at N68 reduced the amount of enzyme 
in the supernatant as a result of reduced stability of the propeptide-mature complex within the 
cell.  Within the ProC motif, mutations at I181 and A183 again decreased the accumulation of 
the active enzyme in the supernatant.  These mutations generated a phenotype consistent with a 
defect due to protein folding or stability. Further research on these mutants could elucidate the 
defective role of these residues as either folding or important for secretion. 
α – Lytic Protease and Other Examples of Propeptide-Mediated Folding    
The biological behavior of all proteins is managed by adopting specific 3D structures, 
and understanding these protein-folding mechanisms is currently a noteworthy area of research.  
Specifically, researchers are examining structure-function relationships.  Proteins have been 
shown to unfold and refold in vitro, restoring activity (Wolynes, Onuchic, & Thirumalai, 1995).  
However, a large group of proteins fail to refold correctly without aid.  These molecular 
chaperones can use peptide-chaperone functions to guide proper folding or ATP hydrolysis to 
refold misfolded proteins (Nirasawa, Nakajima, Zhang, Yoshida, & Hayashi, 1999; Shinde & 
Inouye, 1993; Shinde & Inouye, 1996; Shinde & Inouye, 2000; Xu, Horwich, & Sigler, 1997).  
Propeptide domains are produced by both prokaryotic and eukaryotic organisms (Khalil, 1999). 
The amino-terminal propeptides are usually located between a signal peptide and then the mature 
domain.  After mediating folding of the mature domain, the propeptides are removed and the 
properly folded mature domain is found to be at an energy minimum, a state which cannot be 
attained without the chaperone aid.  Detailed examinations have been performed on α-lytic 
protease to examine its propeptide folding mechanism (Baker, Silen, & Agard, 1992; Baker, 





1988; Silen & Agard, 1989; Silen, Frank, Fujishige, Bone, & Agard, 1989; Sohl, Shiau, Rader, 
Wilk, & Agard, 1997; Sohl, Jaswal, & Agard, 1998).   
α-lytic protease (Figure 7) and its propeptide have been extensively examined for its folding and 
activation mechanism.  The presence of the propeptide has been found necessary for secretion 
and activity of the mature domain by lowering the kinetic barrier of the mature to fold (Silen et 
al., 1989). A common assumption in protein folding is that native protein states are at a global 
energy minimum.  Alpha-lytic protease, an extracellular serine protease from Lysobacter 
enzymogenes, shatters that assumption.  Research has shown that, in vivo and in vitro, its 
propeptide region (166 amino acids) is required for the correct folding of the mature domain 
(199 amino acids) either in cis or in trans (Silen & Agard, 1989).  Experiments aimed at 
examining the in vitro refolding chemically-denatured the mature domain in the absence of pro 
(Baker, Sohl et al., 1992).  This resulted in a folded intermediate.  The presence of the propeptide 
domain led to the rapid formation of the native state of the mature domain.  Without the 
propeptide, the progression of the intermediate to the native folded conformation is blocked by a 
large kinetic barrier.  The rate of folding without the propeptide was measured to be t1/2  of 
~2,000 years, corresponding to a folding barrier of 30 kcal mol
–1
.  The addition of the propeptide 
accelerates the rate of mature enzyme folding by a factor of 3 x 10
9
.  Furthermore, the rate of 
unfolding of the native state appears to be slow as well (t1/2  of ~1 year), suggesting it is not 
energetically favorable to unfold once folded correctly.  The propeptide is making the mature 














Figure 7.  (A) The ribbon diagram of the propeptide alone of alpha-lytic protease from the 
bacterium Lysobacter enzymongenes. 
(B) The ribbon diagram of the propeptide complexed with the mature domain.  The two globular 
regions of the mature domain are shown in purple and blue.  The carboxyl terminal residues of 






















Deletions made to the propeptide residues, specifically the C-terminal residues, indicate 
that these residues actively participate in the stabilizing of the intermediate state (Peters et al., 
1998; Sohl et al., 1997).  The crystal structure of the complex revealed that the propeptide is 
“C”-shaped and completely surrounds the carboxyl domain of the mature enzyme, protecting the 
mature domain and allowing it to fold correctly.  The propeptide’s C-terminal residues actually 
sit in the active site.  The final steps of mature folding take place within the active site.  Once 
complete, the active site cleaves the flexible loop containing the propeptide C-terminal residues; 
thus the loop is acting as an Achilles heel.  This allows for the propeptide to dismantle its foldase 
role safely from the mature. This important step is followed by rapid proteolytic destruction of 
the rest of the propeptide, thus releasing the active enzyme. 
Scope of this Project 
 This thesis describes how I further characterized the propeptide of elastase as a “foldase”.  
The proteolytic activity and secretion of elastase is dependent on the ability of the propeptide to 
act as a chaperone, to aid in the folding of the mature domain, and to works as an inhibitor in 
order to prevent the activity of the enzyme before secretion.  Understanding folding mechanisms 
can be difficult due to the short-lived intermediate states. However, the two individual 
components can be manipulated independently and synergistically.   
 Initial experiments suggest that the propeptide domain alone has a native folded structure.  
This was accomplished through a number of biochemical and theoretical approaches.  The 
propeptide was examined with circular dichroism and crystallization screens to identify the 
presence and nature of its secondary structure.  Molecular homology modeling provided a visual 
of what that structure looked like.  This model was then used to dock to the crystal structure of 





experiments were utilized to characterize the protein-protein interactions between the elastase 
and propeptide complex. Alignments to other M4 metallopeptidases found a number of 
conserved residues in the propeptide domain.  Numerous alanine substitutions were made and 
tested for in vitro and in vivo effects on the ability of the mutated propeptide to aid in folding and 
secretion of the complex.  By testing for both in vivo and in vitro effects, the mutations could 
suggest the roles of individual residues as specific for folding or secretion.  Furthermore, the 
residues could be localized on the model to see if these critical residues could be reasonable 
folding mutants or secretion mutants.  The identification of the critical residues in the propeptide 
could lead to a better understanding of how the propeptide acts as a foldase for the mature, 








Strains used, culture media and conditions. P. aeruginosa PAO1 is a clinical isolate from a 
burn wound used in the Ohman laboratory.  P. aeruginosa PDO426 [ propeptide] contains
 
a 
chromosomal deletion of the propeptide domain only of lasB in the lab standard strain PAO1. 
This was used
 
as an elastase-deficient strain background for expression of
 
the propeptide alleles 
with mutations. Escherichia
 
coli DH5α fhuA2Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 
gyrA96 recA1 relA1 endA1 thi-1 hsdR17 (New England Biolabs) was used to propagate DNA 
which
 
was subjected to site-directed mutagenesis and used in the manipulation of recombinant 
plasmids. Bacteria
 
were cultured in L broth (1% tryptone, 0.5 % yeast extract,
 
0.5 % NaCl, 
pH 7·5) in shaking cultures at 37°C. Unless specified otherwise,
 












General PCR and recombinant DNA methods. Most routine DNA manipulations were 
performed as described by
 
Maniatis et al. (T. Maniatis, E. F. Fritsch, J. Sambrook, 1982). DNA 
sequences were determined by the
 
automated technique with custom oligonucleotides (ACGT, 
Inc). Sequence
 
comparisons were performed using the basic local alignment search
 
tool 
(BLAST) algorithm, aligned with ClustalW programs and visualized with GoCore software. 
Enzymes belonging
 
to the TNP family had significant homologies within
 
the protease domain of 
their molecules.
   
 
Recombinant Propeptide Purification. The propeptide domain (lacking pre and mature 





amino terminal His-6 tag, in E. coli BL21 (DE3). Strains were
 
grown to mid-log phase (A580, 0.5 
to 0.8). Isopropyl-β-D-thiogalactopyranoside
 
(IPTG) was added to a final concentration of 1 mM 
and cultures
 
were incubated for an additional 4 h at 37°C with shaking.
 
250 ml of pelleted cells 
were resuspended in 10.0 ml fractionation buffer with
 
8M urea (10 mM Tris-HCl [pH 8.0], 100 
mM NaCl). The suspension was stored at –70°C overnight,
 
thawed, and lysed with a French 




Thermo Electron). Cells were centrifuged at 4°C twice at
 
14,000 x g 
for 20 min. The supernatant was filtered through
 
a 0.45-µm acrodisc filter, and 10.0 ml were 
applied to an equilibrated nickel resin column (Qiagen). The
 
liquid was allowed to drain by 
gravity flow. The column was
 
washed four times with 10 ml of wash buffer (fractionation buffer 
with 50 mM imidazole). His6-Propeptide was eluted stepwise with 500 µl
 
of 1.0 M imidazole in 
fractionation buffer. Elutes were pooled
 
and dialyzed overnight at 4°C against 10 mM Tris-HCl 
[pH 8.0], 100 mM NaCl buffer to remove imidazole.
 
 
Production of Propeptide Antibody.  Polyclonal antisera against recombinant His6-Propeptide 
(over expressed as above and sent in a SDS-PAGE piece sample) was generated
 
in New Zealand 
White rabbits (Immunodynamics, Inc.) and used
 
in a Western immunoblot analysis at a dilution 
of 1:10,000.
 
Signal detection with chemiluminescent reagents was performed
 
according to the 
instructions of the manufacturer (Pierce).  
 
Polyacrylamide gel electrophoresis and immunoblot analysis. Protein samples were separated 
and analyzed on a 12% SDS-polyacrylamide gel electrophoresis (PAGE) (Laemmli, 1970). 
Protein samples were prepared for SDS-PAGE by heating for 5 min at 100°C in an equal volume 
of 2X sample buffer (0.1 M Tris-HCl, 5 % SDS, 0.9 % 2-mercaptoethanol (2ME), 20 % glycerol, 





MO) in ethanol: acetic acid: water (30:10:60, v/v/v). A broad-range protein weight marker (Bio-
Rad, Hercules, CA) was used for protein size determination. For western blot analysis, proteins 
were similarly separated by SDS-PAGE and electrophoretically transferred to a nitrocellulose 
membrane by electroblotting using a Bio-Rad Immuno-Blot assay kit. Antiserum against the 
purified propeptide was raised in rabbits as described previously.  Antiserum against purified 
elastase was obtained previously in the lab. Detection of the primary antibody on nitrocellulose 
membranes was revealed with horseradish-peroxidase conjugated goat anti-mouse IgG (Bio-
Rad) at a 1:40,000 dilution. Thermo Scientific SuperSignal chemiluminescence reagents were 
used according to manufacturer’s instructions 
 
Purification of active elastase. A lasB over expression vector was created by double digestion 
with NcoI and HindIII of the PCR product wild-type lasB gene and placed into a broad host 
range expression vector pMF54 containing the trc promoter and lacI
Q
 for IPTG induction.  When 
this plasmid (pALH79) was expressed in the ΔlasB strain, PDO240, and induced, ten times more 
elastase was secreted as compared to wild-type.  Three liters of this strain was then grown in L 
broth with maximum aeration at 37°C for 18 hours.  Cells were collected by centrifugation and 
resuspended in fresh media containing IPTG for four hours of protein induction.  Cells were 
removed by centrifugation and the supernatant is filtered to remove cellular debris.  Elastase was 
then precipitated by 60% ammonium sulfate saturation and the pellet was collected by 
centrifugation.  The pellet was resuspended in small volume of 10mM Tris buffer, pH 7.5, 
dialyzed and applied to an equilibrated DEAE-sepharose column.  The column was washed with 





containing the elastase were collected and analyzed for protein concentration via the Bradford 
assay, activity, and purity.  
Elastase Activity Substrates.  Proteolytic activity from Pseudomonas can be assayed with 
casein or azocasein whereas elastinolytic activity is determined with elastin–Congo Red or 
orcein–elastin (Rust, Messing, & Iglewski, 1994).  Elastin nutrient agar plate assays can also be 
used to detect elastase production by P. aeruginosa (Rust et al., 1994). However, specific and 
sensitive elastase activity was determined spectrophotometrically with the fluorogenic substrate 
Abz-Ala-Gly-Leu-Ala-Nba (Abz: o-aminobenzoyl; Nba: 4-nitrobenzylamide) (Bachem).  
 
Assay of in vivo enzymatic activity. To obtain standardized cultures of P. aeruginosa strains, L
 
broth was inoculated (1:100) with an overnight culture and
 
then grown once the cultures reached 
an OD600 of 0.5. This was then used to
 
inoculate (1:100) 10 ml of L broth and incubated at 37
 
°C 
with aeration for 18 h into early stationary phase,
 
at which time extracellular elastase is stable 
and has reached
 
a plateau. Elastolytic activity in 18 h culture supernatants
 
was determined using 
a fluorogenic substrate, Abz-Ala-Gly-Leu-Ala-p-Nitro-Benzyl-Amide (Pepnet), which contained 
a short span of amino acids susceptible to cleavage by elastase surrounded by donor and 
quencher fluorophores.  When this substrate was in the presence of enzyme, the quencher 
fluorophore was removed and the donor emission is determined.  Various concentrations of 
substrate (final assay concentration = 0.0125 mM - 0.2mM) were prepared in DMSO and added 
to 0.05M TrisHCl, pH 7.5, 2.5mM CaCl2 buffer in black Costar 96 well plates and prepared in 
the BioTek FLx800 fluorescence microplate reader.  Aliquots of supernatants were added and 
fluorescence was determined immediately, every 11 seconds for 20 minutes.  The excitation and 
emission wavelengths were 320 and 415 nm respectively.  The device was standardized using 2.5 





substrate concentration was determined and Lineweaver-Burk plots were constructed to 
determine Km values for each propeptide mutant. These values were expressed in molarity (μM).  






The propeptide domain alone folds into a defined structure. 
 
Introduction to Vibriolysin 
 The M4 family of proteases has been classified in the MEROPS database.  Within this 
family, several of these proteases are initially synthesized as zymogens.  These zymogen forms 
contain propeptides that are essential for proper folding of the mature enzymes.  These 
propeptides are defined as intramolecular chaperones (McIver et al., 1995; Nickerson, Joag, & 
McGavin, 2008).  Members of this family are generally synthesized as pre-proenzymes with an 
amino-terminal (pre) signal sequence.  This domain is then followed by a propeptide domain and 
finally a mature enzyme domain on the carboxy-terminus. 
 In addition to elastase, another family member has recently been crystallized that shares 
homology (51% identity, 68% similarity) to the zymogen form of elastase (Gao et al., 2010).  
This new zymogen is vibriolysin, a thermolysin-like protease.  Vibriolysin MCP-02 was isolated 
from Pseudoalteromonas species SM9913: the mature domain and inactive complex were 
crystallized and archived in the Protein Database (mature: 3NQX, inactive complex: 3NQY).  
The zymogen structure of vibriolysin is similar to the zymogen of pro-elastase. Both have a 23 
amino acid signal peptide at the amino-terminus.  Both have a long propeptide (vibriolysin’s is 
180 amino acids while elastase’s is 174) that contains the two fold regions of conservation: the 
FTP (fungalysin/thermolysin propeptide) domain and the PepSY (peptidase propeptide inhibitor) 
domain.  Vibriolysin’s mature domain is 315 amino acids in length, and it is composed of two 
globular domains linked together.  Between the two globular domains is the conserved HEXXH 





HEXXH motif, similar in elastase. Vibriolysin, however, contains an additional carboxyl-
terminal domain, PPC (bacterial pre-peptidase C-terminal domain).  These crystallization and 
biochemical studies however were performed with variations of the enzymes that lacked this 
PPC domain.  The domain has been found at the carboxyl-terminus of certain secreted bacterial 
peptidases, but these are not present in the active peptidase form. 
 The similarity between the two zymogens suggested the propeptide from elastase would 
function by an analogous mechanism.  The two propeptide domains (Figure 8) aligned with a 
high degree of identity (32%) and similarity (52%), particularly in the two conserved fold 
regions, FTP and PepSY.  When the whole zymogens were aligned (Figure 9), the sequence 
identity was 51% and the sequence similarity was 68%.  This provided a strong rationale for 
performing a number of biochemical experiments to determine if the propeptide from elastase 
had native structure.  The first approach utilized was circular dichroism. 
Circular dichroism results 
 Circular dichroism (CD) is the differential absorption of left- and right-handed circularly 
polarized light.  When polarized light (at selected wavelengths) reaches the molecule, the two 
types are absorbed to different extents, and this difference is measured yielding the CD spectrum 
of the sample (Dodero, Quirolo, & Sequeira, 2011).  Three recombinant amino terminal histidine 
tagged propeptide samples were purified and dialyzed overnight in 5 mM phosphate buffer, and 
the CD spectrum average (Figure 10) was then obtained using a Jasco J-720 spectrometer 
equipped with a thermal peltier temperature control module (University of Richmond, Dr. 
Dattelbaum).  All the measurements were performed using protein solutions of 1 uM in 5 mM 












Figure 8.  This is the sequence alignment of the propeptide domain of elastase (LasB) and the 
propeptide domain of vibriolysin.  The residues in orange are those in the Fungalysin-
Thermolysin propeptide domain, and those in green are in the PepSY domain.  The ProM region 
is highlighted above the residues indicated in red.  The ProC region is highlighted in blue.  
Residues that were identical were labeled with an “*”.  Those residues that were conserved in the 












Figure 9.  Shown is the alignment of the mature domains of elastase and vibriolysin.  The 
propeptide region is shown in Figure 8 and remains the same when the whole gene product is 
aligned.  Residues that were identical were labeled with an “*” and conserved in the alignment 












Figure 10. The circular dichroism analysis of the purified recombinant propeptide, which 
suggests has a predominantly beta strand conformation.  The graph shows the wavelengths 
across the x axis at which the ellipticity (y axis) was obtained.  This is an average of three 






(ver. 5.1.0.0). This confirmed it was composed primarily of beta strands. The circular dichroism 
signature is 51% beta strands; the remaining is alpha helices and random coils.  Further analysis 
(K2d web server algorithms) of the propeptide’s raw data suggests this CD signature is 
composed of primarily beta strands.  The circular dichroism data obtained gave confidence to 
proceed to the next biochemical step which would focus on identifying if the propeptide domain 
alone could grow crystals as for x-ray crystallization. 
Crystallization screen results 
Based on the suggested presence of a defined structure for the propeptide domain alone, 
recombinant propeptide was purified and sent to Hauptman-Woodward Medical Research 
Institute for inclusion in their high-throughput screening (HTS) laboratory (Luft et al., 2003).  
The lab prepares crystal-growth screening experiments in 1536-well microassay plates for 
propeptide crystallization screening.  Amino terminal histidine tagged propeptide samples (600 
microliters) at a concentration of 10 mg/ml were prepared and sent to the institute.  Aliquots of 
the propeptide protein were then mixed individually with 1536 unique crystallization cocktails 
(provided by Hampton Research) by a robotic system for the microbatch-under-oil crystallization 
method.  Each cocktail condition, each in its own well, was then imaged several times (at day 1, 
week 1, week 2, week 3, week 4, week 5, and week 6).  These images could then be viewed and 
determined if crystals have grown. 
 Several conditions produced crystals, and these crystals grew larger as the weeks passed.  
The largest of the crystals (Figure 11A) was seen at week 4.  The cocktail reagent for this well 
was 1.6 M Ammonium Sulfate, 0.1 M MES monohydrate, 10% 1,4-Dioxane.  Additional wells 
produced large crystals, and some of these can be seen in Figure 11B-E.  The ability of the 











Figure 11.  Images of elastase were obtained of the different crystallization cocktails at week 4.  
These are shown as A-E.  The dimension of the well are as labeled.  The diameter of each well is 
0.9 mm.  Cocktail condition for well A is 1.6 M Ammonium Sulfate, 0.1 M MES monohydrate, 
10% 1,4-Dioxane.  The cocktail condition for well B is HR Grid Screen Salt HT-A10 -- 1.6 M 
Ammonium sulfate, 0.1 M HEPES, pH 7.0.  The cocktail condition for well C is HR Grid Screen 
Salt HT-B2 – 2.4 M Ammonium sulfate, 0.1 M Citric acid, pH 5.0.  The cocktail condition for 
well D is HR Grid Screen Salt HT-H12 – 4 M Sodium chloride, 0.1 M BICINE, pH 9.0.  Finally, 
the cocktail condition for well E is HR HT Screen G8 – 0.1 M Sodium Chloride, 0.1 M HEPES, 






defined structure.  To examine what the structure could look like, molecular modeling methods 
were next employed.   
 
Molecular modeling results 
Having already determined that the propeptide sequence of elastase aligns with the 
sequence of the propeptide of vibriolysin from Pseudoalteromonas sp. SM9913, this allowed me 
to use molecular modeling techniques to obtain a structure for the propeptide of elastase.  This 
was accomplished using FUGUE. FUGUE assesses sequence similarity, but then quantifies these 
similarities in the context of a known 3D structure; it defines a structural environment in terms of 
main-chain conformation, secondary structure, solvent accessibility and also hydrogen bonding 
status. FUGUE uses environmentally specific substitution tables and structure-dependent gap 
penalties, where scores for amino acid matching and insertions/deletions are evaluated depending 
on the local environment of each amino acid residue in a known structure (Shi, Blundell, & 
Mizuguchi, 2001).  Utilizing the ORCHESTRAR homology modeling program in the SYBYL 
software package, a 3D model of the propeptide was built by first modeling conserved cores, 
then variable regions (loops),  based on the FUGUE predicted homolog. Side chains were added 
and finally the energy was minimized in SYBYL, which is able to remove steric clashes at the 
subunit interfaces (Dolan, Keil, & Baker, 2008).  
The FUGUE database scans all the structures in the Protein Database and provided a 
structural homolog with a high homology score (28.5).  A FUGUE Z-score of 6 gives a 99% 
confidence analysis the unknown structure will align to the known structure (Shi et al., 2001). 
The propeptide sequence was 32% identity with its identified homolog, vibriolysin from 











Figure 12. A model of elastase based on the structure of the vibriolysin propeptide was created of 
the propeptide domain alone. (A) Shown is a ribbon diagram with the beta strands and alpha 
helices highlighted.  (B) Shown is a space filled representation, with amino-terminal alanine 






FTP and PepSY folds.  Modeling programs then built the structure of the propeptide around the 
known crystal structure of vibriolysin’s propeptide and assessed the fit. The propeptide of 
elastase has a high confidence analysis when analyzed by I-TASSER program (Zhang, 2008) as 
well.  This I- TASSER server performs the same search as FUGUE and generates a model 
(Figure 12).  It then matches the predicted 3D model to the known structures in 3 independent 
libraries (consisting of proteins of known enzyme classification number, gene ontology 
vocabulary, and finally ligand-binding sites) and generates a TM-score in a range of -5 to +2.  
The TM-score for the model of the elastase propeptide was +0.93.  The model also confirmed the 
presence of primarily beta strands (Figure 12A indicated with large wide arrows). 
Molecular model Docking results 
 Once a model of the propeptide’s 3D structure was generated and analyzed, it could then 
be used to predict the propeptide-mature complex structure.  The Hex protein docking server 
constrains a structure in a 3D field and uses charge and size of the residues on the structures to fit 
the other structure into a predicted 3D complex (Ritchie, 2008).  In this case, the crystal structure 
of mature elastase was constrained, and the propeptide model was assessed at various positions 
around the mature domain.  One such resulting complex (Figure 13A) was very similar to the 
complex (Figure 13B) of the propeptide and mature domains of Vibriolysin.  In both these 
structures, the propeptide’s carboxy-terminal residue is a histidine and it resides in the active site 
of the mature domains.  In addition, the propeptides appear to be a “C” shape, which cups around 
carboxyl globular domain of the mature. 
 To confirm that the propeptide of elastase can function as an intramolecular chaperone, it 
was critical to first establish that it has a native structure providing stability to the complex.  A 











Figure 13.  The elastase propeptide model was docked to the 3D structure of the mature active 
enzyme using the Hex protein docking server.  Space filling representations were used for both 
the (A) propeptide-elastase complex and the (B) propeptide-vibriolysin complex.  The propeptide 
domains are shown in green with its amino-terminal residue show in dark orange and its 
carboxy-terminal residue in yellow.  The mature domains are shown in red with the active site 






native secondary structure and its type.  The evidence from the circular dichroism experiments 
and molecular modeling suggest the propeptide primarily has a beta sheet conformation.  The 
docking model enables a visual interpretation of how the propeptide could be interacting with the 
mature domain and these will be helpful in the next series of experiments in which the roles of 







The propeptide has conserved residues that affect folding and activation of the mature 
 
Alignment of the propeptide to other M4 metalloprotease propeptides 
 The previous research on the role of elastase’s propeptide established that it was required 
for folding and secretion of the mature domain.  From my previous experiments that suggest the 
propeptide had a defined structure, one could deduce that there are critical residues in this 
structure important for the folding and activation of the mature domain.  To narrow down the 
residues which could be critical, a sequence alignment of the propeptide from elastase to other 
propeptides of M4 metalloproteases was performed in order to identify those conserved among 
the different propeptides. 
Propeptides with homology to the elastase propeptide were first identified by a search of 
the protein database using Basic Local Alignment Search Tool (BLAST). The amino acid 
sequences for the propeptide were then aligned (Figure 14) to the elastase propeptide according 
to the BLAST results using the NCBI ClustalW server(Thompson, Higgins, & Gibson, 1994).  
The sequences found by the BLAST are: elastase LasB of P. aeruginosa (LasB); Class 4 
metalloprotease of Chromobacterium violaceum ( Class 4 metalloprotease); metalloprotease 
from Listonella anguillarum (metalloproteinase); neutral protease/zince metalloprotease from 
Salinivibrio proteolyticus (neutral protease); VtpA protease from Vibrio tubiashii (VTPA); 
hemagglutinin/proteinase of V. cholerae (hemagglutinin/proteinase); protease from Aeromonas 
punctata (protease); proaminopeptidase protease from Aeromonas punctata (pro-

















Figure 14. A BLAST search with the elastase propeptide sequence and ClustalW alignment 
indicates there are conserved residues among the propeptides.  A “*” symbol indicates amino 
acid identity; a “:” symbol indicates similarity; empty spaces represent gaps in similarity 
introduced by the ClustalW alignment program.  Residues in bold are those chosen based on 
conservation and selected for mutation.  The regions were designated ProM and ProC, and the 
signal sequence is depicted with the first residue of the propeptide numbered 24. The sequences 
shown are the propeptides of : elastase LasB of P. aeruginosa (LasB); Class 4 metalloprotease of 
Chromobacterium violaceum ( Class 4 metalloprotease); metalloprotease from Listonella 
anguillarum (metalloproteinase); neutral protease/zince metalloprotease from Salinivibrio 
proteolyticus (neutral protease); VtpA protease from Vibrio tubiashii (VTPA); 
hemagglutinin/proteinase of V. cholerae (hemagglutinin/proteinase); protease from Aeromonas 
punctata (protease); proaminopeptidase protease from Aeromonas punctata (pro-







Those residues boxed in grey were then chosen based on conservation and were mutated to 
alanines.  By investigating the phenotype of the conserved residues, the ability of the propeptide 
to fold and activate the mature domain will be indicated in the final elastase activity.   
Construction of mutants in the propeptide alleles to operate in trans 
 The construction of these alleles encoding the alanine substitutions in the propeptide 
sequence was performed via oligonucleotide-directed site-specific mutagenesis.  This PCR 
technique was based on the QuikChange Site-Directed Mutagenesis system (Stratagene) as 
described by the manufacturer.  Single-base-pair substitutions
 
encoding mutant propeptide 
residues were introduced within
 
the plasmid pVM8.  This template plasmid contained the
 
wild-
type lasB gene signal sequence domain and regulatory region on a 2·5 kb
 
EcoRI–PstI fragment in 
pUCP19 and lacked the mature domain of the gene and encoded for a stop codon after the 
propeptide domain. The original wild-type methylated plasmid, pVM8, was used in the PCR 
steps.  DpnI was then used to cleave the template strain and the mutated plasmid was 
transformed into DH5α cells.  Site-specific
 
substitutions were verified by DNA sequence 
analysis to generate the pEB40 series of plasmids. These pEB40 clones were mobilized into the 
P. aeruginosa lasB-deficient
 
strain PDO426 by triparental mating with HB101 
(pRK2013)(Figure 15). Plasmid pVM8, with the wild-type
 
lasB propeptide domain in the 
plasmid pUCP19, was used as a positive control.  The empty vector pUCP19 was used as a 
negative control.  
 The utilization of the ability of the propeptide to act in trans on the mature domain is 
beneficial to this assay.  The single substitutions of conserved residues to alanine on the 
propeptide were generated and the plasmids were introduced to the background strain.  Both the 











Figure 15.  This figure depicts the schematic used to measure the effects of the mutated 
propeptides on elastase in vivo.  The background strain lacks the propeptide domain only 
(PDO426) and the propeptide is brought in trans by either pVM8 (wild-type) or the pEB40 






used the quorum-sensing regulation systems to synthesize the two components.  The two 
components could then translocate through the inner membrane.  The mutated residues in the 
propeptide interact with the mature domain within the periplasmic space.  The complex was then 
secreted and the elastase activity was assessed in the supernatant (protocol described in the 
Methods).  A range of substrate concentrations was utilized to obtain the KM value for each 
propeptide.  This allowed for the comparison of the wild-type propeptide to the mutant 
propeptide’s ability to fold and secrete the mature domain without the final secreted enzyme 
concentration as a factor. 
Assessment of those mutant propeptides in vivo 
The ability to measure the kinetics of the enzyme (the enzyme’s affinity for the substrate) 
without the concentration of enzyme as a factor is critical for this analysis.  Those mutant 
residues that have little effect on the folding and secretion of the complex act like wild-type 
propeptide and yield similar KM values (substrate affinity values).  However, if the mutant 
propeptide residues have an effect on the ability to fold, activate and secrete the mature domain, 
the effect could be so drastic that the misfolded complex accumulates in the cell and is 
eventually degraded with so little to no activity is measured outside the cell. 
First order Michaelis-Menten kinetics describes the affinity between the enzyme and the 
substrate (Kou, Cherayil, Min, English, & Xie, 2005).  The KM value is the inverse of the 
enzyme affinity for the substrate.  The enzyme affinity for the substrate will reflect how the 
propeptide aids in folding and secretion.  By harvesting the enzyme at the peak of its production, 
the enzyme is assumed to have completed its interaction with the propeptide and thus free to 
cleave the substrate.  Utilizing the sensitive fluorogenic substrate, determination of even minimal 











Figure 16.  Wild-type elastase was used to determine the affinity for the fluorogenic substrate.  A 
range of final substrate concentrations were used to determine the reaction rates and plotted in 
the (A) Michealis-Menten graph.  This graph indicates the enzyme is undergoing first-order 
single substrate enzyme kinetics.  The inverse of the reaction rates and the inverse of the 
substrate concentrations were plotted in the (B) Lineweaver-Burk plot to yield the Km value (the 






concentrations were nefated and comparisions of how the residues in the propeptide affected the 
enzyme’s activation were able to be made. 
Initial experiments were performed to determine the optimal substrate concentrations used to 
assay the mutants.  Wild-type elastase was tested with a range of substrate concentrations and the 
rate of each reaction at the individual substrate concentrations, was plotted in the Michaelis-
Menten diagram (Figure 16A).  The inverse of reaction rates and the inverse of the substrate 
concentrations were then plotted in a Lineweaver-Burk plot (Figure 16B) to determine the KM.  
A linear regression through the points was generated, and the inverse of the X axis value yielded 
the KM.  A previously published experiment determined the KM value for elastase and this 
specific fluorogenic substrate to be 0.11 mM (Nishino & Powers, 1980).  The value obtained was 
also 0.11 mM.  Then a range of substrate concentrations encompassing the KM were employed to 
test the different propeptide mutant alleles.  In the assay, the enzyme samples were tested with 
the final substrate concentrations of 0.0125 mM, 0.025 mM, 0.05 mM, 0.1 mM, 0.15 mM, and 
0.2 mM to provide the different reaction rates.  These rates were then assembled into 
Lineweaver-Burk plots in order to assess each mutant’s effect on mature activity.  If the 
mutatated residue in the propeptide had minimal effect, then the closer the KM value was to wild-
type.  The more damaging the effect of the mutated residue, the larger the KM value grew, 
indicating a poor average affinity of the enzyme for the substrate. 
 A bar graph (Figure 17) was constructed to display the KM values.  Because the residues 
that were chosen were conserved it is not surprising that all of the mutant propeptides had an 
impact on the KM value of resulting enzyme, with some more than others. Mutations to the G69, 
E143, P177, H178, and E187 residues had values closer to wild-type, implying these residues 











Figure 17. The fold change of the KM values are depicted for the in vivo analysis.  The mutant 
elastase propeptide alleles KM values were expressed as fold change from the wild-type KM 
value.  The blue asterisk indicated residues that were unable to produce enzyme activity to 






Mutations, however, to a large number of other propeptide residues caused a large value 
change in KM, indicating that those elastase variants had less affinity for the substrate.  These 
propeptides had a diminished capacity to aid in the folding of the complex.  These propeptides 
include D25, K59, R62, L66, P67, K70, R74, Y75, E76, Q77, G81, R83, V84, V85, G105, D114, 
S118, Q127, N144, D145, L149, L153, E155, L161, V162, Y163, V165, S166, S175, I181, 
D182, A183, G186, W192, E193, G194, and L195.  Each of these mutant propeptides caused at 
least a 10-fold difference to the KM compared to wild-type. 
There were five mutants that produced so little active enzyme that the KM value could not 
be determined.  These were indicated as a blue asterisk on the bar graph “*”.  These residues 
included N68A, Q102A, R176A, T185A, and H197A.  Each of these residues appears to be polar 
and could be essential for protein-protein interactions.    
These conserved residues that were mutated and shown to affect the affinity of the 
enzyme to the substrate could be impacting mature elastase in several different ways.  There 
could be residues that are found in the interior of the propeptide and help stabilize the 
propeptide’s structure.  Residues could lie on the exterior of the propeptide and be important for 
recognition for the complex by the Type 2 transport system.  Additionally, there could be 
residues that reside at the interface of the propeptide-mature complex that provide anchors for 
the mature domain.  Disrupting any of these residues could impact the KM value of the resulting 
enzyme. 
Construction of mutant propeptides to be expressed as recombinant propeptides 
In order to separate the role of the individual residues, several residues were chosen from 
the in vivo data.  Propeptides with residues that produced fold-changes of at least 50-fold 





next set of experiments.  These residues include R62, L66, P67, N68, R74, Q102, S118, Q127, 
N144, D145, R176, T185, W192, E193, G194, L195, and H197 for the Propeptide – Mediated In 
vitro Foldase Activity Assay. 
This assay (Figure 18) utilized recombinant propeptide and active elastase that were 
denatured individually and then renatured together at 4°C.  The renatured enzyme was then 
assayed as before using the fluorogenic substrate.  The active enzyme was purified from the 
supernatants of Pseudomonas cultures and tested for initial activity.  Recombinant propeptide 
(wild-type and mutants) were generated with an amino-terminal histidine tag.  However, the 
template plasmid was pEB2, which encodes a signal sequence, a histidine tag, a thombin 
cleavage site and the propeptide domain alone in the pET28b vector (see Methods).  This 
allowed for the purification of the mutant recombinant propeptides on a nickel column.   
Once the two individual components were purified, they were denatured using 6 M 
Guanidine-HCl, which allowed for the now inactive enzyme to retain its disulphide bonds.  The 
two denatured components were mixed together at a 1:1 ratio of 3 µM each and dialyzed against 
0.05 M TrisHCl (pH 7.0) at 4°C, with the buffer changed four times each hour.  An aliquot was 
taken and combined trypsin to ensure the propeptide degraded and the active site was now clear.  
The sample was then assayed using the same protocol as the in vivo assay, replacing the quantity 
of supernatant with the same quantity of refolded sample.  The enzyme was mixed with buffer, 
and the range of substrate concentrations and the KM were evaluated.  The KM value here allows 













Figure 18.  Shown is a schematic of the propeptide-mediated in vitro foldase activity assay for 
elastase.  Active elastase enzyme is denatured with guanidine HCl.  Recombinant propeptide is 
denatured as well.  These two components are then mixed 1:1 and dialyzed against TrisHCl 
buffer to dialyze away the guanidine HCl, allowing the two proteins to complex and fold.  The 
final activity of the enzyme can then be assayed as a reflection of how well the mutant 






Assessment of the mutant recombinant propeptides in vitro 
 By utilizing this in vitro assay, the effects of the propeptide on secretion can be ignored.  
This is similar to examining what is happening in the periplasm before the complex is recognized 
by the secretion system.  These mutant propeptides are only now able to fold into the 
propeptide’s secondary structure and complex with mature domain. These allowed for the 
classification of several residues in the propeptide that could be important for secretion 
recognition, i.e., these propeptides produced near wild-type KM values now they are free from 
the secretion apparatus even though in the in vivo assay they had drastic effects. 
The KM values are depicted in a bar graph (Figure 19).  Alanine substitutions at N68, 
S118, Q127, D145 and T185 had values similar to the wild-type propeptide.  This suggests that 
these substitutions only function similarly to wild-type since they aren’t required to be 
recognized by the secretion apparatus.  However, residues such as R62 L66, P67, R74, N144, 
W192, E193, G194, and L195 again had large differences between their KM values and that of 
wild-type.  These residues could be critical for the propeptide’s stability or exist at the interface 
when complexed with mature and are now unable to perform their function. 
Several residues (Q102, R176, and H197) were unable to fold elastase in vitro into native 
structure and their KM values could not be determined.  This suggests these residues are essential 
for their role in folding the mature domain into active enzyme. 
These conserved residues, discovered by alignment to other M4 metalloproteases, appear 
to be vital for the maturation and activation of the enzyme.  Diminished enzyme activity was 
found in both the in vivo and the in vitro assays. Three dimensional examination of the location 
of these residues within the complex would allow for the surrounding environment of the 














Figure 19. The fold changes of the KM values for elastase variants are depicted.  The mutant 
recombinant propeptide KM values were expressed as fold change from the wild-type KM value.  








The mutant residues in the propeptide are in critical 3D locations to function. 
 
Determining the role of individual residues within the propeptide 
 Substitutions in several of the conserved residues were found to have a deleterious effect 
on the ability of the mature enzyme to fold, activate or be recognized by the secretion apparatus.  
An analysis of the ability of the propeptide within the cell to recover the mature domain’s 
activity in trans provided further confirmation that the propeptide was acting as an 
intramolecular chaperone.  Additionally, these mutant residues were examined outside the cell to 
provide insight into the individual roles the residues could be playing.   
 To further clarify the potential roles of the individual residues, a bar graph of both sets of 
data (Figure 20) was developed.  The data provided by in vivo analysis (Figure 17) is shown in 
blue bars with blue asterisks indicating values not determinable due to the absence of enzyme.  
The data provided in the in vitro analysis (Figure 19) is shown in red bars and red asterisks.  
Here one can now compare how an individual residue performed in each case.  For instance, R62 
when mutated to alanine, performed poorly in both the cell system and the cell-free system.  
Additional members of this group include L66, P67, R74, N144, W192, E193, G194, and L195.  
These propeptides with substitutions did not perform better when the enzyme and mutant 
versions of the propeptide were tested outside the cell in the in vitro assay.  This suggests that 
these residues have little or no role in secretion recognition of the complex. 
 However several residues, N68, S118, Q127, D145, and T185, might have a critical role 
in secretion recognition.  These mutant propeptides performed poorly and diminished the 














Figure 20. The fold change values found in Figures 17 and 19 were simplified and plotted with 
corresponding colors.  The in vivo assay produced fold change values indicated by the blue bars 
and blue asterisks.  The in vitro assay produced fold change values indicated by the red bars and 






the in vivo assay.  These substitutions still allowed the ability of the propeptide to fold and 
activate the mature domain but only if free from the cell and the secretion apparatus.  
There were three residues, Q102, R176, and H197, which appear to have lost all ability to 
fold the mature domain into an active enzyme, both in vivo and in vitro.  In the cell, the effects of 
enzyme production could not be measured using the refolding assay.  This suggests these 
residues are intrinsically important for the ability of the enzyme to fold.  These polar residues 
were hypothesized to form essential protein interactions at the interface of the complex. 
 Examining the location of these conserved residues on the model of the complex 
provided a rationale for how these residues were impacting the structure and stability.  The 
residues found to be critical for secretion (N68, S118, Q127, D145, and T185) can be seen near 
the exterior of the complex (Figure 21).  The three dimensional placement of these residues 
suggests they are free to interact with the secretion apparatus, thus signaling the cell that the 
complex is ready to be secreted. 
 Those mutant propeptides that diminished all ability for the enzyme to activate elastase in 
both the in vivo and the in vitro analysis (Q102, R176, and H197) were located on the complex 
model as well.  All three residues were found (Figure 22) to be at the interface of the complex, 
potentially making protein-protein interactions with the mature domain.  The H197 residue in the 
elastase- propeptide complex appears to be in the same location as the final histidine residue on 
the complex of Vibriolysin and its propeptide (Gao et al., 2010).  In that case, the vibriolysin 
propeptide acts as an inhibitor as the C terminus of the propeptide inserts into the catalytic cleft.  
The carboxyl group of that final histidine actually replaces the activated water molecule in the 
mature enzyme.  This enables the histidine residue to act as a ligand to the zinc ion.  Without that 













Figure 21.  The critical propeptide residues implicated in secretion are N68, S118, Q127, D145, 
and T185.  These images of the models are depicted where the mature domain is red, the 
propeptide is green.  The active site residues of the mature domain are colored black.  The amino 
terminal residue of the propeptide is colored orange; the carboxy terminal is yellow.  The amino 
terminal residue of the mature domain is colored blue and the carboxy terminal residue is purple.  













Figure 22.  The critical propeptide residues implicated in elastase activation are Q102, R176, and 
H197.  These images of the models are depicted where the mature domain is red, the propeptide 
is green.  The active site residues of the mature domain are colored black.  The amino terminal 
residue of the propeptide is colored orange; the carboxyl terminal is yellow.  The amino terminal 
residue of the mature domain is colored blue and the carboxyl terminal residue is purple.  The 






hydrolysis in addition to the propeptide physically blocking the cleft.  The propeptide thus is 
inhibiting activity of the mature domain in the propeptide-vibriolysin complex.   
In addition to those residues, there were a number of mutant propeptide residues that 
performed poorly in the in vivo assays as well as the in vitro assays.  These residues (R62, L66, 
P67, N144, W192, E193, G194, and L195) could have either of the roles listed previously or 
could help control the propeptide stability.  These models (Figure 23) provided some 
explanations.  The R62, L66, P67, and N144 residues all appear to reside near the interface of the 
complex.  Changing these residues to alanines diminished their ability to provide a fully 
functional interface for the mature domain to be activated.  The residues closer to the carboxyl-
terminus of the propeptide (W192, E193, G194, and L195) could be important in aiding the final 
histidine residue (H197) in blocking the catalytic cleft.  Substituting any of these residues for an 
alanine could make the C-terminal tail less rigid, unable to act as an inhibitor while the mature 
domain folds and activates completely. 
System for the production of stable propeptide-mature complexes. 
These models provide a valuable tool for providing explanations for the individual 
residues’ roles.  But a clearer picture can be developed from future structure studies.  To generate 
a complex such as the crystallized propeptide-vibriolysin complex, an inactive mature domain 
was needed (Figure 24).  For easier purification of this complex, a Strep-Tag was employed.  An 
allele containing the upstream region containing the lasB promoter, the pre signal domain, the 
mature domain with an E141D mutation (inactive), the Strep-Tag (EMD4Biosciences), and 
downstream region to allow for homologous recombination was generated using splicing by 
overlap-extension PCR(Horton et al., 1993; Mergulhao, Kelly, Monteiro, Taipa, & Cabral, 1999; 













Figure 23.  The critical residues implicated in unknown yet important function are R62, L66, 
P67, N144, W192, E193, G194, and L195.  These images of the models are depicted where the 
mature domain is red, the propeptide is green.  The active site residues of the mature domain are 
colored black.  The amino terminal residue of the propeptide is colored orange, the carboxy 
terminal is yellow.  The amino terminal residue of the mature domain is colored blue and the 
carboxy terminal residue is purple.  The residues that are implicated in secretion are depicted as a 














Figure 24. A schematic of a genetic approach to produce tagged inactive propeptide-elastase 
complex for purification.  The top illustration is the gene diagram seen in a previous figure 
but helps to orientate.  The pre-inactive mature-strep tag construct was produced using 
SOEing and cloned into the suicide vector, pEX18ApGW.  This suicide construct was then 
conjugated into a lasB deficient strain to cross into the host chromosome.  The pre-pro allele 
was brought back in trans.  The inactive mature strep-tagged domain was then capable of 






(Choi & Schweizer, 2005) and conjugated into a Pseudomonas ΔlasB strain for homologous 
recombination.  A vector containing the upstream regulatory region of lasB, the pre signal 
sequence and the propeptide domain was generated and conjugated into the new strain.  
Now the inactive tagged mature domain and the propeptide domain can fold within the 
periplasm to make an inactive complex for easy purification.  This inactive tagged complex 
of mature and propeptide, where the propeptide won’t be degraded, can now be used for a 
number of biochemical studies such as hydrogen/deuterium exchange mass spectrometry in 
order to determine the residues at the interface of the complex or  x-ray crystallography in 
order to determine the entire complex’s structure.   
           The modeling of the propeptide domain to the mature provided a visual representation to 
support the residue mutations and explain the data.  Several of the propeptide residues when 
substituted were shown to be on the exterior of the complex were unable to recover the ability of 
the enzyme to be active in the in vivo assay while the activity was able to be recovered in the in 
vitro assay.  Residues that showed diminished capability to aid in the mature domain’s ability to 
activate were also shown to be localized to the interface and interior of the propeptide, providing 
stability to the propeptide’s native structure and stability and inhibition to the mature domain.  
To further elucidate just how these residues at the interface interact with the mature domain, a 
new construct was developed to harness a tagged version of the inactive complex.  Together, 
these results indicate there are critical residues within the propeptide that should be studied 






Summary and future directions 
 
 This dissertation contains research elucidating the ability of the propeptide of elastase, an 
M4 metalloprotease secreted by Pseudomonas aeruginosa, to act as an intramolecular chaperone 
through the use of several individual investigations into the structure of the propeptide and the 
role of individual residues (McIver et al., 1995).  Each independent project resulted in new 
discoveries of the mechanisms required by the propeptide to aid in folding, activation and 
secretion of the mature domain.  The following summarizes the findings from each project 
culminating with a discussion regarding future studies. 
 Previous research on similar zymogens has shown that the propeptide can act as an 
intramolecular chaperone for the mature domain, controlling the enzyme’s activation and 
secretion.  To elucidate just how the propeptide from elastase performs this function, a number 
of biochemical techniques were employed.  It is currently unknown whether propeptide is 
capable of folding into a defined structure in order to aid mature activation within the complexed 
form of the two proteins.  The recombinant propeptide was generated in E. coli to enable easier 
attainment than harvesting the native protein from periplasmic fractions or carefully timed, 
washed cellular supernatants.  This recombinant propeptide allowed for milligram quantities to 
be purified quickly using affinity chromatography.  Utilizing this purified form of recombinant 
propeptide, a series of circular dichroism measurements were obtained.  The analysis of the 
signatures revealed the recombinant propeptide had a primarily beta sheet secondary structure.  
The purified recombinant propeptide was also subjected to a microassay-based system of 





certain crystallization cocktails supports the conclusion that the propeptide has native secondary 
structure.  Molecular modeling techniques were then utilized to determine what this propeptide 
could look like.  Database searches returned a crystallized structure of the propeptide-vibriolysin 
complex and a high degree of homology of both domains to the sequence of elastase and its 
propeptide.  Homology modeling provided a three dimensional illustration of what the 
propeptide could look like based on the known propeptide structure from vibriolysin.  The 3D 
model was analyzed based on the sequence homology and the score resulted in a 99% confidence 
analysis that the predicted structure is the correct structure.  These investigations provided 
convincing evidence that the propeptide domain alone folds into a defined structure.  The ability 
of the propeptide to have its own defined structure supports the mechanism employed by the 
propeptide studied extensively in the α-lytic protease activation(Anderson, Peters, Wilk, & 
Agard, 1999; Baker et al., 1992; Baker, Sohl et al., 1992; Bone, Frank, Kettner, & Agard, 1989; 
Bone, Fujishige, Kettner, & Agard, 1991; Cunningham, Jaswal, Sohl, & Agard, 1999; 
Cunningham, Mau, Truhlar, & Agard, 2002; Derman & Agard, 2000; Fuhrmann, Kelch, Ota, & 
Agard, 2004; Fujishige, Smith, Silen, & Agard, 1992; Jaswal, Sohl, Davis, & Agard, 2002; 
Jaswal, Truhlar, Dill, & Agard, 2005; Mace & Agard, 1995; Mace, Wilk, & Agard, 1995; Peters 
et al., 1998; Rader & Agard, 1997; Sauter et al., 1998; Silen et al., 1988; Silen & Agard, 1989; 
Silen et al., 1989; Sohl et al., 1997; Sohl et al., 1998; Truhlar & Agard, 2005).  For alpha-lytic 
protease, the structured propeptide (“C” shaped or cup shaped) allows for the propeptide to 
encompass the carboxyl terminal domain of the mature domain.  The mature domain is then 
protected to fold and activate.   
 In order to examine the purpose of the specific residues within the propeptide, a ClustalW 





other M4 metalloprotease sequences.  This alignment produced a large number (47 residues) of 
conserved residues that were then individually substituted with alanine.  These mutant 
propeptide alleles were expressed in trans within a Pseudomonas ΔlasB propeptide host.  The 
mutant propeptides were synthesized by the cell and free to interact with the mature domain in 
the periplasm.  Utilizing this system, the activity was measured outside the cell as a reflection of 
how the mutant propeptides were aiding the mature domain in its ability to aid in folding, 
activation and secretion.  Each of these mutant propeptides had an effect on the ability to act as 
an intramolecular chaperone for the mature domain, some more than others.  Certain substituted 
residues, such as G69, K70, E143, P177, and E187 had only a small effect on the mature domain, 
resulting in KM values closer to wild-type.  Other residues like N68, Q102, R176, T185, and 
H197 had such drastic effects on the mature domain folding and secretion that no mature was 
secreted and the KM value could not be determined.  Other mutant residues resulted in large 
changes to the KM value, suggesting these residues are critical as well.   
 To examine more clearly the role of each residue, one can employ a technique to 
eliminate one role.  This technique will negate the effect of the residue to be recognized by the 
secretion apparatus.  The residues within the propeptide could have been contributing to the 
stability of the propeptide’s secondary structure, sustaining interactions at the interface of the 
complex or being critical for the recognition of the Type 2 secretion system.  The propeptide-
mediated in vitro foldase assay utilized mutant recombinant propeptides and active enzyme.  The 
two components were individually purified, denatured, and recombined to renature into complex 
form.  The activity detected was then descriptive of the ability of the propeptide to act as an aid 
to folding and activation, not secretion.  Residues were identified that had been poor in the vivo 





T185).  These residues were suggested to be essential for recognition by the secretion apparatus.  
A different set of residues (R62, L66, P67, R74, N144, R176, W192, E193, G194, and L195) 
lacked the ability to aid in folding and activation in both assays. This suggests these residues are 
critical for the propeptide to maintain its structure and could exist at the interface of the complex. 
These kinetic analyses overwhelmingly support the critical nature of these conserved residues. 
 Developing a three dimensional model of where these conserved residues are located, 
assisted in the further assessment of the residues’ roles.  Polar residues implicated in the role of 
secretion were examined and determined to be along the exterior of the complex and could easily 
interact with components of the secretion apparatus to signal the cell to secrete the complex.  
Residues implicated in folding were also examined and were found to reside along the interior of 
the propeptide or the interior of the complex.  This suggests their critical role to stabilize the 
propeptide’s structure and create an interface for the mature domain to attach.  To further 
corroborate the role of these residues, a construct was developed to capture an inactive version of 
the complex (no degradation of the propeptide) employing a Strep-Tag. This construct could now 
be used for a variety of biochemical techniques to confirm the structure of the complex and the 
location of individual residues. 
 These examinations provided further supporting evidence to support the role of the 
propeptide as an intramolecular chaperone to the mature domain of elastase.  The ability of the 
propeptide to have a defined native structure and conserved residues verified to be critical for the 
mechanism of activation and secretion, present a clearer understanding of how the propeptide is 
aiding in folding and providing inhibition to the activity before the complex is secreted into the 
medium.  Future studies would address the folding and binding mechanism required of the 





 Structural studies will confirm the residues in the complex to be exterior or interior to the 
complex.  The crystal screens performed previously can be repeated and optimized to produce 
crystals large enough for diffraction.  The crystals via x-ray crystallography could provide the 
3D structure of the native propeptide protein to confirm the model.  Furthermore the crystallized 
structure of the propeptide could then be docked to the crystallized structure of the mature to 
confirm the docked complex model.  In addition purifying the inactive complex and performing 
crystallization screens, optimization, and diffraction, can be utilized for eventual x-ray 
crystallography for the determination of the whole complex structure.  A quicker approach for 
the inactive complex could yield the residues that are at the interior of the proteins and the 
complex interface.  Amide hydrogen/deuterium exchange mass spectrometry technology by the 
ExSAR Corporation would provide the residues that are buried within the complex by the 
difference in hydrogen/deuterium exchange rates (Yoshitomo Hamuro, Lora L. Hamuro, Stephen 
J. Coales, Virgil L. Woods Jr., ).  Hydrogens along the exterior of the complex will exchange 
with the deuterium faster than those on the interior.  The reaction is quenched, the complex is 
degraded, and mass spectrometry identifies the peptides that were deuterated.  These results will 
provide not only the residues within the propeptide that exist at the interface, but additionally the 
residues within the mature domain at the interface.  Mutations to mature domain would allow for 
assessment of their ability to recover or compensate mutant propeptide residues.  This structural 
data would also lead to further understanding of the mechanism employed by the propeptide to 
be an IMC for the mature domain, i.e., what’s happening within the periplasm.    
An additional examination might include studying the ability of the propeptide to 
bind to the mature domain.  If the KM value from mutant propeptides was different from the 





domain to form that complex. Differential scanning calorimetry (DSC) on the recombinant 
mutant propeptides compared to wild-type would determine the relative stability of these 
mutant propeptides, confirming those residues thought to be critical for propeptide’s native 
structure(Sanchez-Ruiz, 2011).  DSC could also be important for the assessment of mutant 
propeptides in complex with mature.  The ability of the propeptides to be stabilizers to the 
complex would be reflected in this technique.  Isothermal titration calorimetry could be 
performed on an inactive mature domain and the propeptide domain to determine the 
energy involved in the binding reaction (Ladbury, 2010).  When two proteins bind, heat is 
either absorbed or generated and this thermodynamic technique measures the differences in 
heat to provide an assessment of the thermodynamic profile (the binding constants, 
enthalpy and entropy of the reaction).  Optimizing these series of experiments would also 
eventually be useful for examination of the mutant propeptides.  Moreover, this technique 
has its advantages compared to surface plasmon resonance (SPR), that it provides the 
additional thermodynamics besides the binding affinities. 
Ultimately, these experiments provide a sound basis for supporting the ability of the 
propeptide to act as an intramolecular chaperone via its structure and roles of the conserved 
residues, and a goal for future research to elucidate the steps the propeptide takes to 
perform this function.  Illuminating the way a protein proceeds from this primary amino 
acid sequence to its final native state is a current intense field of research, providing 
explanations to the structure-function relationships. 
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Table 1. pEB40 series and pEB41 of plasmids encoding for mutant propeptides. 
 
Name of plasmid What it is 
pEB40 pUCP19 with EcoRI-PstI fragment of the lasB region including the 
upstream regulatory region, the pre-signal sequence, the wild-type 
propeptide domain and a stop codon 
pEB40.D25A pEB40 encoding a D25A substitution within the propeptide domain 
pEB40.K59A pEB40 encoding a K59A substitution within the propeptide domain 
pEB40.R62A pEB40 encoding a R62A substitution within the propeptide domain 
pEB40.L66A pEB40 encoding a L66A substitution within the propeptide domain 
pEB40.P67A pEB40 encoding a P67A substitution within the propeptide domain 
pEB40.N68A pEB40 encoding a N68A substitution within the propeptide domain 
pEB40.G69A pEB40 encoding a G69A substitution within the propeptide domain 
pEB40.G69D pEB40 encoding a G69D substitution within the propeptide domain 
pEB40.K70A pEB40 encoding a K70A substitution within the propeptide domain 
pEB40.R74A pEB40 encoding a R74A substitution within the propeptide domain 
pEB40.Y75A pEB40 encoding a Y75A substitution within the propeptide domain 
pEB40.E76A pEB40 encoding a E76A substitution within the propeptide domain 
pEB40.Q77A pEB40 encoding a Q77A substitution within the propeptide domain 
pEB40.G81A pEB40 encoding a G81A substitution within the propeptide domain 
pEB40.R83A pEB40 encoding a R83A substitution within the propeptide domain 
pEB40.V84A pEB40 encoding a V84A substitution within the propeptide domain 
pEB40.V85A pEB40 encoding a V85A substitution within the propeptide domain 
pEB40.Q102A pEB40 encoding a Q102A substitution within the propeptide domain 
pEB40.G105A pEB40 encoding a G105A substitution within the propeptide domain 
pEB40.D114A pEB40 encoding a D114A substitution within the propeptide domain 
pEB40.S118A pEB40 encoding a S118A substitution within the propeptide domain 
pEB40.Q127A pEB40 encoding a Q127A substitution within the propeptide domain 
pEB40.E143A pEB40 encoding a E143A substitution within the propeptide domain 
pEB40.N144A pEB40 encoding a N144A substitution within the propeptide domain 
pEB40.D145A pEB40 encoding a D145A substitution within the propeptide domain 
pEB40.L149A pEB40 encoding a L149A substitution within the propeptide domain 
pEB40.L153A pEB40 encoding a L153A substitution within the propeptide domain 
pEB40.E155A pEB40 encoding a E155A substitution within the propeptide domain 
pEB40.L161A pEB40 encoding a L161A substitution within the propeptide domain 
pEB40.V162A pEB40 encoding a V162A substitution within the propeptide domain 
pEB40.Y163A pEB40 encoding a Y163A substitution within the propeptide domain 
pEB40.V165A pEB40 encoding a V165A substitution within the propeptide domain 
pEB40.S166A pEB40 encoding a S166A substitution within the propeptide domain 
pEB40.S175A pEB40 encoding a S175A substitution within the propeptide domain 
pEB40.R176A pEB40 encoding a R176A substitution within the propeptide domain 
pEB40.P177A pEB40 encoding a P177A substitution within the propeptide domain 





pEB40.I181A pEB40 encoding a I181A substitution within the propeptide domain 
pEB40.D182A pEB40 encoding a D182A substitution within the propeptide domain 
pEB40.A813G pEB40 encoding a A183G substitution within the propeptide domain 
pEB40.T185A pEB40 encoding a T185A substitution within the propeptide domain 
pEB40.G186A pEB40 encoding a G186A substitution within the propeptide domain 
pEB40.E187A pEB40 encoding a E187A substitution within the propeptide domain 
pEB40.W192A pEB40 encoding a W192A substitution within the propeptide domain 
pEB40.E193A pEB40 encoding a E193A substitution within the propeptide domain 
pEB40.G194A pEB40 encoding a G194A substitution within the propeptide domain 
pEB40.L195A pEB40 encoding a L195A substitution within the propeptide domain 
pEB40.H197A pEB40 encoding a H197A substitution within the propeptide domain 
pEB41 pET28b encoding for an amino terminus Histidine-6 tag, thrombin 
cleavage site and propeptide domain under expression of Ptrc 
pEB41.D25A pEB41 encoding a D25A substitution within the propeptide domain 
pEB41.K59A pEB41 encoding a K59A substitution within the propeptide domain 
pEB41.R62A pEB41 encoding a R62A substitution within the propeptide domain 
pEB41.L66A pEB41 encoding a L66A substitution within the propeptide domain 
pEB41.P67A pEB41 encoding a P67A substitution within the propeptide domain 
pEB41.N68A pEB41 encoding a N68A substitution within the propeptide domain 
pEB41.G69A pEB41 encoding a G69A substitution within the propeptide domain 
pEB41.G69D pEB41 encoding a G69D substitution within the propeptide domain 
pEB41.K70A pEB41 encoding a K70A substitution within the propeptide domain 
pEB41.R74A pEB41 encoding a R74A substitution within the propeptide domain 
pEB41.Y75A pEB41 encoding a Y75A substitution within the propeptide domain 
pEB41.E76A pEB41 encoding a E76A substitution within the propeptide domain 
pEB41.Q77A pEB41 encoding a Q77A substitution within the propeptide domain 
pEB41.G81A pEB41 encoding a G81A substitution within the propeptide domain 
pEB41.R83A pEB41 encoding a R83A substitution within the propeptide domain 
pEB41.V84A pEB41 encoding a V84A substitution within the propeptide domain 
pEB41.V85A pEB41 encoding a V85A substitution within the propeptide domain 
pEB41.Q102A pEB41 encoding a Q102A substitution within the propeptide domain 
pEB41.G105A pEB41 encoding a G105A substitution within the propeptide domain 
pEB41.D114A pEB41 encoding a D114A substitution within the propeptide domain 
pEB41.S118A pEB41 encoding a S118A substitution within the propeptide domain 
pEB41.Q127A pEB41 encoding a Q127A substitution within the propeptide domain 
pEB41.E143A pEB41 encoding a E143A substitution within the propeptide domain 
pEB41.N144A pEB41 encoding a N144A substitution within the propeptide domain 
pEB41.D145A pEB41 encoding a D145A substitution within the propeptide domain 
pEB41.L149A pEB41 encoding a L149A substitution within the propeptide domain 
pEB41.L153A pEB41 encoding a L153A substitution within the propeptide domain 
pEB41.E155A pEB41 encoding a E155A substitution within the propeptide domain 
pEB41.L161A pEB41 encoding a L161A substitution within the propeptide domain 
pEB41.V162A pEB41 encoding a V162A substitution within the propeptide domain 
pEB41.Y163A pEB41 encoding a Y163A substitution within the propeptide domain 





pEB41.S166A pEB41 encoding a S166A substitution within the propeptide domain 
pEB41.S175A pEB41 encoding a S175A substitution within the propeptide domain 
pEB41.R176A pEB41 encoding a R176A substitution within the propeptide domain 
pEB41.P177A pEB41 encoding a P177A substitution within the propeptide domain 
pEB41.H178A pEB41 encoding a H178A substitution within the propeptide domain 
pEB41.I181A pEB41 encoding a I181A substitution within the propeptide domain 
pEB41.D182A pEB41 encoding a D182A substitution within the propeptide domain 
pEB41.A813G pEB41 encoding a A183G substitution within the propeptide domain 
pEB41.T185A pEB41 encoding a T185A substitution within the propeptide domain 
pEB41.G186A pEB41 encoding a G186A substitution within the propeptide domain 
pEB41.E187A pEB41 encoding a E187A substitution within the propeptide domain 
pEB41.W192A pEB41 encoding a W192A substitution within the propeptide domain 
pEB41.E193A pEB41 encoding a E193A substitution within the propeptide domain 
pEB41.G194A pEB41 encoding a G194A substitution within the propeptide domain 
pEB41.L195A pEB41 encoding a L195A substitution within the propeptide domain 
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